Trial Profile
A Single-Center, Randomized, Double-Blind, Double-Dummy Placebo Controlled, Cross-Over Study to Investigate the Next Morning Effects of Ramelteon (8mg), Zopiclone (7.5mg) and Placebo on Actual Driving Performance, Memory Functioning, Psychomotor Performance in Adults with Chronic Insomnia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Ramelteon (Primary) ; Zopiclone (Primary)
- Indications Insomnia
- Focus Therapeutic Use
- Sponsors Takeda
- 03 Apr 2022 Status changed from recruiting to completed.
- 07 Oct 2011 Takeda has discontinued the development of ramelteon in Europe for the treatment of insomnia.
- 25 Jul 2011 New trial record